Onyda XR Shortage: What Providers and Prescribers Need to Know in 2026

Since its FDA approval in May 2024 and commercial launch in the second half of 2024, Onyda XR (clonidine hydrochloride extended-release oral suspension) has generated strong interest among prescribers treating pediatric ADHD. As the first and only liquid non-stimulant ADHD medication, it fills a genuine clinical gap — particularly for younger children or those who struggle to swallow pills.

However, providers are increasingly reporting that patients are having difficulty getting their prescriptions filled at local pharmacies. This post gives you a clinical overview of the availability situation and actionable strategies to help your patients.

Current Shortage Status

As of early 2026, Onyda XR is not listed on the FDA's official Drug Shortage Database, nor on the ASHP shortage list. However, widespread pharmacy-level stocking problems are being reported, particularly at smaller independent pharmacies and some community chain locations. The issue appears to be a new drug distribution challenge — not a manufacturing shortage — but the patient impact is the same.

Why Onyda XR Availability Is Uneven

Several factors converge to create distribution gaps:

Single-source brand with no generic. All supply routes through Tris Pharma. There is no therapeutic AB-rated generic equivalent for the extended-release oral suspension formulation.

New-to-market stocking latency. Pharmacies adjust ordering patterns to historical demand. A medication that launched in late 2024 hasn't built the demand history needed to trigger automatic reorder thresholds at many locations.

Ongoing stimulant shortage spillover. Continued demand pressure from Adderall and methylphenidate shortages is driving more patients toward non-stimulants, increasing Onyda XR prescriptions faster than pharmacies have scaled their inventory.

Specialty liquid handling requirements. Extended-release oral suspensions are typically stocked in lower volumes than tablets or capsules, and some pharmacies may not have established sourcing relationships for this product type from Tris Pharma's distributors.

Clinical Considerations When Prescribing Onyda XR

When prescribing Onyda XR for a new patient, the following guidance helps reduce the likelihood of prescription abandonment due to availability:

Call ahead or use your EHR's pharmacy lookup. Before sending a new Rx, verify the patient's pharmacy has Onyda XR in stock or can order it.

Recommend a specific pharmacy. Hospital-affiliated outpatient pharmacies and large chain pharmacies (CVS, Walgreens, Walmart) are more likely to have stock or be able to order it within 1–3 business days.

Consider 90-day mail-order fills. Since Onyda XR is not a controlled substance, mail-order dispensing is permitted. Encourage patients with commercial insurance to explore their plan's mail-order benefit.

Counsel on not stopping abruptly. Educate patients and caregivers that Onyda XR must not be discontinued suddenly due to the risk of rebound hypertension. If they anticipate a supply gap, they should contact your office immediately.

Pharmacokinetic Cautions: Not Interchangeable With Other Clonidine Products

Onyda XR should not be substituted for Kapvay (clonidine ER tablets) or generic clonidine ER tablets on a milligram-per-milligram basis. The FDA prescribing information explicitly states these products have different pharmacokinetic profiles. Ctrough,ss for Onyda XR is approximately 26% lower than an equivalent dose of clonidine ER tablets at steady state. Dose recalculation is required if switching formulations.

When to Consider Alternative Non-Stimulant Agents

If your patient consistently cannot fill Onyda XR and a liquid formulation is not medically required, consider:

Guanfacine XR (generic Intuniv): Same class (alpha-2 agonist), once-daily dosing, generic widely available, approved ages 6–17

Clonidine ER tablets (generic Kapvay): Same active ingredient, twice-daily tablets, generic available — dose adjustment required

Atomoxetine (generic Strattera): Different mechanism, once or twice daily, generic available, approved 6+; note boxed warning for suicidal ideation in pediatric patients

Viloxazine XR (Qelbree): Non-stimulant, once daily, approved 6–17, no generic available

Important Prescribing Note: Rebound Hypertension Risk

Ensure patients and caregivers understand the rebound hypertension risk associated with abrupt discontinuation. Patients with gastrointestinal illnesses causing vomiting are particularly at risk for missed doses. Counsel caregivers to contact your office before stopping and to monitor for symptoms including headache, tachycardia, nausea, flushing, and chest tightness.

Resources to Help Your Patients Find Onyda XR

Point patients to medfinder for providers, which calls local pharmacies on the patient's behalf to check stock. The Tris Savings Card at TrisSavingsCard.com allows eligible commercially insured patients to pay as little as $25 per month.

For a complete provider resource guide, see: How to Help Your Patients Find Onyda XR in Stock: A Provider's Guide.